Eur Heart J. 2006;27:1038–47.PubMedCrossRef 8. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, CH5424802 molecular weight and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–51.PubMedCrossRef 9. Wallentin L, Becker RC, Budaj A,
et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.PubMedCrossRef 10. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute LY3039478 cost myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.PubMedCrossRef 11. NewsRx. Medication Compliance: 40% of American adults report difficulty in swallowing pills. http://www.newsrx.com/newsletters/Biotech-Business-Week/2004-02-09/02092004333452BB.html. Accessed 18
April 2013. 12. Carnaby-Mann G, Michael Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg. 2005;131:970–5.PubMedCrossRef 13. Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Pract. 2005;15:411–4. 14. White R, Bradnam V. Handbook of drug administration via enteral feeding tubes. http://www.pharmacy.cmu.ac.th/unit/unit_files/files_download/2012-03-26HandbkOfDrugAdminiViaEnteralFeedingTubes%201stEd_WhiteAndBradn.pdf VX-689 cost Accessed 16 Jan 2013. 15. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet. 2005;366:1607–21.PubMedCrossRef 16. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral
P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary Endonuclease syndromes. J Am Coll Cardiol. 2007;50:1852–6.PubMedCrossRef 17. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599–605.PubMedCrossRef 18. AstraZeneca. Data on file: clinical study D5130C00055. 19. AstraZeneca. Data on file: AstraZeneca formulation development report–taste prediction of ticagrelor by an electronic tongue.”
“1 Introduction While the number of hypertensive patients is increasing in most countries because of longevity and unhealthy lifestyles, the control rate of hypertension remains low in many countries, such as China.